The Learning Portal will be under maintenance Saturday, 8 August between 6 AM and 6 PM EST. Portal functionality will be unavailable during this window.
We apologize for any inconvenience caused during this time.

RAPS is closely monitoring developments in the Coronavirus (COVID-19) outbreak. See our public safety page for the latest updates.

 
  • Regulatory NewsRegulatory News

    FDA Approves First DTC Tests Evaluating Genetic Risk Information

    The US Food and Drug Administration (FDA) on Thursday authorized the first direct-to-consumer (DTC) genetic health risk tests for 10 diseases and conditions. The authorization for the genetic testing company 23andMe means individuals for the first time will be able to use these tests to understand their genetic predispositions for certain diseases and conditions without first seeing a doctor. “Consumers can now have direct access to certain genetic risk information,”...
  • Regulatory NewsRegulatory News

    FDA Finalizes Guidance on Neurological Device Trials

    The US Food and Drug Administration (FDA) on Friday finalized its guidance for sponsors looking to submit an investigational device exemption (IDE) to conduct clinical trials for neurological devices targeting disease progression in diseases such as Alzheimer's and Parkinson's. "FDA believes that neurological devices intended to slow disease progression and improve clinical outcomes that are meaningful to patients may represent a revolutionary option for patients," FDA w...
  • Regulatory NewsRegulatory News

    EMA Official: Data Sharing and Collaboration Can Fill Scientific Gaps in Alzheimer's

    Speaking at a panel at RAPS' 2016 Convergence on Monday, Enrica Alteri, head of human medicines research and development support at the European Medicines Agency (EMA) called on drugmakers to share data to close the gaps in Alzheimer's disease (AD) research. According to Alteri, doing so could help the scientific community not only learn from past failures in Alzheimer's research, but enable the development and validation of new targets. Scientific Gaps "There are gaps...
  • Regulatory NewsRegulatory News

    Neurological Device Trials: FDA Offers Draft Guidance

    The US Food and Drug Administration (FDA) on Friday released draft guidance to assist sponsors who intend to submit an investigational device exemption (IDE) to conduct clinical trials on medical devices targeting neurological disease progression, including for Alzheimer’s disease, Parkinson’s disease or primary dystonia. “Medical devices intended to slow, stop, or reverse the effects of neurological disease face challenges with regard to collecting safety and efficacy d...
  • Regulatory NewsRegulatory News

    EMA Offers New Draft Guidance on Developing Alzheimer’s Treatments

    The European Medicines Agency (EMA) on Monday released new draft guidance on the development of Alzheimer’s disease treatments that would allow treatments to be evaluated in earlier disease stages before dementia sets in. The new guidance comes as EMA recognizes that the field of Alzheimer’s disease (AD) research and development “witnessed a recent paradigm shift in the diagnostic framework of AD which is now considered a continuum with a long-lasting presymptomatic phas...
  • Regulatory NewsRegulatory News

    European Regulatory Roundup: Sweden Limits Availability of Paracetamol (5 November 2015)

    Welcome to our European Regulatory Roundup, our weekly overview of the top EU regulatory news. Swedish Regulators Limit Availability of Paracetamol Sweden has prohibited the sale of paracetamol tablets outside of pharmacies. The action follows a decision by the Swedish Medical Products Agency (MPA), which ruled in April to limit where the drug is sold in an attempt to curb the rise in paracetamol poisonings.  MPA’s ruling overturned a decision from 2009, at which ...
  • Regulatory NewsRegulatory News

    FDA: What's Slowing Progress in Some Disease Areas?

    In a post to FDA Voice – the US Food and Drug Administration's blog – recently appointed Deputy Commissioner for Medical Products and Tobacco Robert Califf says progress toward curing some diseases, such as Alzheimer's, is being slowed by a lack of understanding of disease biology. Why are There Effective Treatments for Some Diseases and not Others? Califf raises this question, and points to some diseases like HIV/AIDS, where advances in scientific understanding hav...
  • EMA Calls for Revisions to be Made to Alzheimer's Guideline

    The European Medicines Agency (EMA) has announced the release of a new concept paper calling for the revision of its guideline on the development of products intended to treat Alzheimer's disease "and other dementias," saying a new approach is needed to accommodate patients who are pre-symptomatic or in the early stages of disease progression. The Need for a Guideline The concept paper is similar to a draft guidance released in February 2013 by the US Food and Drug Ad...
  • C-Path Obtains EMA, FDA Approval for Tool to Expedite Development of Alzheimer's Treatments

    The Critical Path Institute (C-Path), a public-private hybrid organization supported directly by the US Food and Drug Administration (FDA), has announced a "big step forward for Alzheimer's disease therapy development," saying that it has obtained the support of FDA and the European Medicines Agency (EMA) to launch a new disease simulation tool intended to improve clinical trial design for investigating Alzheimer's treatments. C-Path, which was founded in 2005 under FDA'...
  • FDA Releases Guidance Document on Alzheimer's Disease

    • 07 February 2013
    • By
    A new draft guidance document released by the US Food and Drug Administration (FDA) seeks to provide sponsors with a better understanding of how it intends to regulate drug products that treat a disease that manufacturers and patients alike have long sought better treatments for: Alzheimer's disease (AD). Background The guidance, Alzheimer's Disease: Developing Drugs for the Treatment of Early Stage Disease , was released on 7 February 2013. FDA explained that eve...
  • Warning Letter to Eli Lilly Focuses on Use of Color Images in Marketing Materials

    The US Food and Drug Administration (FDA) has sent a warning letter to pharmaceutical manufacturer Eli Lilly over alleged deficiencies present in marketing materials distributed by the company through its website, FDA announced on 10 September. The letter, posted on FDA's website by the Office of Prescription Drug Promotion (OPDP), references marketing materials published for Amyvid (Florbetapir F 18 Injection), a positron emission tomography (PET) drug used to help eval...
  • Group Sues FDA, Seeking to Compel it to Withdraw Alzheimer's Drug from Market

    Consumer advocacy group Public Citizen has filed a lawsuit against the US Food and Drug Administration (FDA) seeking to compel it to remove a particular dose of the Alzheimer's drug Aricept, which the group alleges is causing dangerous and potentially fatal side effects. The lawsuit stems from a May 2011 Citizen's Petition filed by the group. The letter, addressed to FDA Commissioner Margaret Hamburg, calls for the 23 mg dose of Eisai's drug Aricept to be removed bec...